![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Population Pharmacokinetic Analysis of Voxilaprevir, a Pangenotypic
HCV NS3/4A Protease Inhibitor in Hepatitis C Virus-Infected Subjects
|
|
|
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL
Brian J. Kirby,1 Erik Mogalian,1 Yuying Gao,2 Anita Mathias1
1Gilead Sciences, Inc., Foster City, California, USA; 2Certara Strategic Consulting, Menlo Park, California
![0622171](../images/062217/062217-3/0622171.gif)
![0622172](../images/062217/062217-3/0622172.gif)
![0622173](../images/062217/062217-3/0622173.gif)
![0622174](../images/062217/062217-3/0622174.gif)
![0622175](../images/062217/062217-3/0622175.gif)
![0622176](../images/062217/062217-3/0622176.gif)
![0622177](../images/062217/062217-3/0622177.gif)
![0622178](../images/062217/062217-3/0622178.gif)
![0622179](../images/062217/062217-3/0622179.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|